General MedicationsINHALATIONStandard
SEREVENT
SALMETEROL XINAFOATE
Standard Dose
EQ 0.05MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SEREVENT is listed in Drugs@FDA under application 020692 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient SALMETEROL XINAFOATE Form and strength POWDER;INHALATION - EQ 0.05MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2019-07-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview SEREVENT is listed in Drugs@FDA under application 020692 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SALMETEROL XINAFOATE Form and strength POWDER;INHALATION - EQ 0.05MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2019-07-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.